SON-1010 (IL12-FHAB)

Phase 1Completed
2 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Adult

Conditions

Healthy Adult

Trial Timeline

Jul 27, 2022 → May 17, 2023

About SON-1010 (IL12-FHAB)

SON-1010 (IL12-FHAB) is a phase 1 stage product being developed by Sonnet BioTherapeutics for Healthy Adult. The current trial status is completed. This product is registered under clinical trial identifier NCT05408572. Target conditions include Healthy Adult.

What happened to similar drugs?

20 of 20 similar drugs in Healthy Adult were approved

Approved (20) Terminated (1) Active (0)

Hype Score Breakdown

Clinical
6
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05408572Phase 1Completed

Competing Products

20 competing products in Healthy Adult

See all competitors
ProductCompanyStageHype Score
Use of Wearable Digital Sensors After mRNA Vaccination in AdultsModernaPreclinical
0
mRNA-0184ModernaPhase 1
0
mRNA-6231ModernaPhase 1
0
LetrozoleDr. Reddy's LaboratoriesPhase 1
26
IsotretinoinDr. Reddy's LaboratoriesPhase 1
26
FexofenadineDr. Reddy's LaboratoriesPhase 1
26
SertralineDr. Reddy's LaboratoriesPhase 1
26
Nizatidine + AxidDr. Reddy's LaboratoriesPhase 1
26
AnastrozoleDr. Reddy's LaboratoriesPhase 1
26
mRNA-1273.712ModernaApproved
0
RisperidoneDr. Reddy's LaboratoriesPhase 1
26
LamotrigineDr. Reddy's LaboratoriesPhase 1
26
Metformin + GlucophageDr. Reddy's LaboratoriesPhase 1
26
LamotrigineDr. Reddy's LaboratoriesPhase 1
26
mRNA-0184ModernaPhase 1
0
Divalproex SodiumDr. Reddy's LaboratoriesPhase 1
26
SirolimusDr. Reddy's LaboratoriesPhase 1
26
GlimepirideDr. Reddy's LaboratoriesPhase 1
26
Ziprasidone HydrochlorideDr. Reddy's LaboratoriesPhase 1
26
Naproxen sodiumDr. Reddy's LaboratoriesPhase 1
26